Murchinson Criticizes the Nano Dimension Board of Directors’ Decision to Pursue a Seemingly Deeply Flawed Transaction with Infinite Epigenetics (opens original article in a new tab)

Murchinson, a major Nano Dimension shareholder, criticizes the board's decision to pursue a transaction with Infinite Epigenetics, citing concerns over the deal's structure, board qualifications, and potential shareholder impact.

• Murchinson criticizes Nano Dimension's board for pursuing a transaction with Infinite Epigenetics, calling it flawed.
• The transaction is compared to a SPAC, with concerns over lack of shareholder redemption rights and board qualifications.
• Shareholders question the board's decision after a stock price drop and potential $10 million termination fee.